Welcome to our dedicated page for Jazz Pharmaceuticals news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals stock.
Jazz Pharmaceuticals plc reports developments across a global biopharma portfolio focused on rare diseases, including epilepsies, cancers and sleep disorders. Recurring updates cover commercial performance for Xywav, Epidiolex and oncology products, plus medical-conference data and real-world evidence for neuroscience and oncology programs.
Company news also includes regulatory and clinical progress for Ziihera (zanidatamab-hrii) in HER2-expressing tumors, including gastroesophageal adenocarcinoma and biliary tract cancer, along with research involving Zepzelca, Modeyso and other pipeline candidates. Updates frequently address financial results, guidance, investor conferences, collaborations and portfolio strategy.
Jazz Pharmaceuticals announces FDA approval of Zepzelca (lurbinectedin) for treating metastatic small cell lung cancer (SCLC) after platinum-based chemotherapy failure. The accelerated approval is based on a clinical study demonstrating a 35% overall response rate (ORR) and a median response duration of 5.3 months. Zepzelca will be available in the U.S. by early July 2020, following a licensing agreement with PharmaMar, effective January 2020. The treatment offers a new option for patients with limited choices, although continued approval depends on further trials confirming its clinical benefits.